Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

CMV driven CD8+ T-cell activation is associated with acute rejection in lung transplantation

(2013) Antoine Roux et al.   CLINICAL IMMUNOLOGY

Immunosequencing: applications of immune repertoire deep sequencing

(2013) Harlan Robins   CURRENT OPINION IN IMMUNOLOGY

A Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells

(2013) Kristin Ladell et al.   IMMUNITY

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells

(2013) Mark Klinger et al.   PLoS One

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

(2012) Saskia J. A. M. Santegoets et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients

(2012) S. S. Kwek et al.   JOURNAL OF IMMUNOLOGY

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

(2010) Begoña Comin-Anduix et al.   PLoS One

Overlap and Effective Size of the Human CD8+ T Cell Receptor Repertoire

(2010) H. S. Robins et al.   Science Translational Medicine

Differential expression analysis for sequence count data

(2010) Simon Anders et al.   GENOME BIOLOGY

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

(2009) L. Fong et al.   CANCER RESEARCH

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

(2008) Begoña Comin-Anduix et al.   Journal of Translational Medicine